Exhibit 99.1

Results of Extraordinary General Meeting

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 April 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) advises that all resolutions considered at the Extraordinary General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

Phillip Hains

Company Secretary

Alterity Therapeutics Limited ACN 080 699 065

Level 3, 62 Lygon Street Carlton Victoria 3053 Australia www.alteritytherapeutics.com